Elevance Health (NYSE:ELV) Stock Unloaded Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Elevance Health, Inc. (NYSE:ELV). In a filing disclosed on May 31st, the Representative disclosed that they had sold between $15,001 and $50,000 in Elevance Health stock on May 15th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Zimmer Biomet (NYSE:ZBH) on 5/15/2025.
• Sold $15,001 – $50,000 in shares of PepsiCo (NASDAQ:PEP) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of WEC Energy Group (NYSE:WEC) on 5/15/2025.
• Purchased $15,001 – $50,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 5/15/2025.
• Purchased $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 5/15/2025.
• Purchased $1,001 – $15,000 in shares of Kraft Heinz (NASDAQ:KHC) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of Danaher (NYSE:DHR) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of International Flavors & Fragrances (NYSE:IFF) on 5/15/2025.
• Purchased $15,001 – $50,000 in shares of Texas Instruments (NASDAQ:TXN) on 5/15/2025.

Elevance Health Stock Down 1.8%

Elevance Health stock opened at $377.08 on Tuesday. The stock’s 50 day moving average price is $413.40 and its 200 day moving average price is $401.21. Elevance Health, Inc. has a 1-year low of $357.45 and a 1-year high of $567.26. The company has a market cap of $85.20 billion, a PE ratio of 14.72, a price-to-earnings-growth ratio of 1.18 and a beta of 0.66. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Tuesday, April 22nd. The company reported $11.97 earnings per share for the quarter, topping analysts’ consensus estimates of $10.60 by $1.37. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. The business had revenue of $48.77 billion for the quarter, compared to analysts’ expectations of $46.26 billion. On average, sell-side analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th will be given a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a yield of 1.81%. The ex-dividend date is Tuesday, June 10th. Elevance Health’s payout ratio is 26.69%.

Hedge Funds Weigh In On Elevance Health

Several hedge funds and other institutional investors have recently modified their holdings of the company. Milestone Asset Management LLC lifted its holdings in shares of Elevance Health by 37.1% during the 4th quarter. Milestone Asset Management LLC now owns 1,098 shares of the company’s stock valued at $405,000 after acquiring an additional 297 shares in the last quarter. Crews Bank & Trust acquired a new position in shares of Elevance Health during the fourth quarter worth about $34,000. Mediolanum International Funds Ltd boosted its position in shares of Elevance Health by 3.4% in the fourth quarter. Mediolanum International Funds Ltd now owns 8,608 shares of the company’s stock worth $3,167,000 after buying an additional 280 shares during the period. Granite Harbor Advisors Inc. grew its stake in shares of Elevance Health by 5.7% in the fourth quarter. Granite Harbor Advisors Inc. now owns 4,198 shares of the company’s stock valued at $1,549,000 after buying an additional 227 shares in the last quarter. Finally, Caprock Group LLC acquired a new stake in shares of Elevance Health in the fourth quarter valued at about $1,989,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Elevance Health

In related news, CAO Ronald W. Penczek sold 443 shares of Elevance Health stock in a transaction on Monday, March 10th. The shares were sold at an average price of $415.13, for a total value of $183,902.59. Following the completion of the sale, the chief accounting officer now owns 1,847 shares in the company, valued at approximately $766,745.11. The trade was a 19.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the completion of the sale, the executive vice president now owns 10,116 shares in the company, valued at approximately $4,008,970.80. This trade represents a 25.73% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,535 shares of company stock worth $3,521,612. 0.29% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Truist Financial boosted their target price on Elevance Health from $480.00 to $510.00 and gave the stock a “buy” rating in a research report on Friday, April 11th. Robert W. Baird reissued a “neutral” rating and issued a $529.00 price objective (down from $625.00) on shares of Elevance Health in a research note on Tuesday, April 15th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Elevance Health in a research report on Friday, March 28th. Royal Bank of Canada restated an “outperform” rating and set a $478.00 price objective on shares of Elevance Health in a research report on Wednesday, April 23rd. Finally, Barclays reduced their target price on Elevance Health from $522.00 to $480.00 and set an “overweight” rating on the stock in a research note on Monday. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $499.53.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.